Real-World Treatment Patterns of Ankylosing Spondylitis
Speaker(s)
Rasouliyan L, Althoff A, Kumar V, Chang S, Long S, Mummert A
OMNY Health, Atlanta, GA, USA
Presentation Documents
OBJECTIVES:
Ankylosing spondylitis (AS) is an inflammatory disease affecting the spine with multisystemic implications. The objective of this research was to characterize treatment patterns of AS patients in the real-world setting.METHODS:
Patients from specialty and integrated delivery networks within the OMNY Health Database with a diagnosis code for AS (ICD-10: M45*) from 2017-2023 were selected. Patients were characterized at first AS diagnosis code. Percentages of patients with prescriptions for following treatments at encounters associated with AS were computed: analgesics/opioids (ibuprofen, naproxen, diclofenac, etoricoxib, acetaminophen, codeine), tumor necrosis factor (TNF) alpha inhibitors (adalimumab, certolizumab, etanercept, golimumab, infliximab), and interleukin (IL) inhibitors (ixekizumab, secukinumab).RESULTS:
A total of 6,171 patients and 7,919 AS-associated encounters were included. Distributions of gender (49% female), race (86% White, 7% Black, 7% Other among known categories), and age (39% > 60 years, 59% 21-60 years, 2% < 21 years) were tabulated. Analgesics/opioids were prescribed at 16% of AS-associated encounters, while TNF alpha inhibitors and IL inhibitors were prescribed at 5% and 1% of AS-associated encounters, respectively. Acetaminophen (11%), adalimumab (3%), and secukinumab (1%) were the most commonly prescribed therapies of each class.CONCLUSIONS:
Results provide insights into real-world therapeutic management of AS in the real-world setting. Future analyses characterizing healthcare resource utilization and associated costs would be helpful to understand the treatment landscape and economic burden of AS.Code
HSD111
Topic
Study Approaches
Topic Subcategory
Electronic Medical & Health Records
Disease
Musculoskeletal Disorders (Arthritis, Bone Disorders, Osteoporosis, Other Musculoskeletal)